These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 24288203

  • 1. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
    Gao YH, An X, Sun WJ, Cai J, Cai MY, Kong LH, Lin JZ, Liu GC, Tang JH, Wu XJ, Chen G, Pan ZZ, Ding PR.
    J Surg Oncol; 2014 Apr; 109(5):478-82. PubMed ID: 24288203
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
    Arbea L, Martínez-Monge R, Díaz-González JA, Moreno M, Rodríguez J, Hernández JL, Sola JJ, Ramos LI, Subtil JC, Nuñez J, Chopitea A, Cambeiro M, Gaztañaga M, García-Foncillas J, Aristu J.
    Int J Radiat Oncol Biol Phys; 2012 Jun 01; 83(2):587-93. PubMed ID: 22079731
    [Abstract] [Full Text] [Related]

  • 6. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
    Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, Tait D, Massey A, Tebbutt NC, Chau I.
    Lancet Oncol; 2010 Mar 01; 11(3):241-8. PubMed ID: 20106720
    [Abstract] [Full Text] [Related]

  • 7. Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.
    Bajetta E, Pietrantonio F, Buzzoni R, Ferrario E, Valvo F, Mariani L, Dotti KF, Biondani P, Formisano B, Gevorgyan A, Grassi P, Di Bartolomeo M.
    Am J Clin Oncol; 2014 Dec 01; 37(6):545-9. PubMed ID: 23428953
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, Tebbutt N, Hill M, Ross PJ, Massey A, Oates J.
    J Clin Oncol; 2006 Feb 01; 24(4):668-74. PubMed ID: 16446339
    [Abstract] [Full Text] [Related]

  • 10. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.
    Zhu J, Gu W, Lian P, Sheng W, Cai G, Shi D, Cai S, Zhang Z.
    Radiat Oncol; 2013 May 29; 8():130. PubMed ID: 23718210
    [Abstract] [Full Text] [Related]

  • 11. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
    Eisterer W, Piringer G, DE Vries A, Öfner D, Greil R, Tschmelitsch J, Samonigg H, Sölkner L, Gnant M, Thaler J, Austrian Breast and Colorectal Cancer Study Group.
    Anticancer Res; 2017 May 29; 37(5):2683-2691. PubMed ID: 28476845
    [Abstract] [Full Text] [Related]

  • 12. Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study.
    Akgun Z, Saglam S, Yucel S, Gural Z, Balik E, Cipe G, Yildiz S, Kilickap S, Okyar A, Kaytan-Saglam E.
    Cancer Chemother Pharmacol; 2014 Oct 29; 74(4):751-6. PubMed ID: 25102935
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.
    Dellas K, Höhler T, Reese T, Würschmidt F, Engel E, Rödel C, Wagner W, Richter M, Arnold D, Dunst J.
    Radiat Oncol; 2013 Apr 15; 8():90. PubMed ID: 23587311
    [Abstract] [Full Text] [Related]

  • 16. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.
    An X, Lin X, Wang FH, Goodman K, Cai PQ, Kong LH, Fang YJ, Gao YH, Lin JZ, Wan DS, Pan ZZ, Ding PR.
    Eur J Cancer; 2013 Mar 15; 49(4):843-51. PubMed ID: 23063351
    [Abstract] [Full Text] [Related]

  • 17. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer.
    Rödel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, Fürst A, Schwella N, Bieker M, Hellmich G, Ewald H, Haier J, Lordick F, Flentje M, Sülberg H, Hohenberger W, Sauer R.
    J Clin Oncol; 2007 Jan 01; 25(1):110-7. PubMed ID: 17194912
    [Abstract] [Full Text] [Related]

  • 18. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
    Cancer and Leukemia Group B 89901Massachusetts General Hospital Cancer Center, Boston MA 02114, USA. dpryan@partners.org, Ryan DP, Niedzwiecki D, Hollis D, Mediema BE, Wadler S, Tepper JE, Goldberg RM, Mayer RJ.
    J Clin Oncol; 2006 Jun 01; 24(16):2557-62. PubMed ID: 16636336
    [Abstract] [Full Text] [Related]

  • 19. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.
    Hasegawa J, Nishimura J, Mizushima T, Miyake Y, Kim HM, Takemoto H, Tamagawa H, Noura S, Fujii M, Fujie Y, Kato T, Miwa H, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M.
    Cancer Chemother Pharmacol; 2014 May 01; 73(5):1079-87. PubMed ID: 24595805
    [Abstract] [Full Text] [Related]

  • 20. Pilot study of intense neoadjuvant chemoradiotherapy for locally advanced rectal cancer: retrospective review of a phase II study.
    Xu BH, Chi P, Guo JH, Guan GX, Tang TL, Yang YH, Chen MQ, Song JY, Feng CY.
    Tumori; 2014 May 01; 100(2):149-57. PubMed ID: 24852858
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.